Stallion India Allots 3.67 Crore Equity Shares at ₹99 per Share; Corrects Face Value to ₹10
Stallion India Fluorochemicals corrected its face value disclosure to ₹10 per share. On 2nd March 2026, the Rights Issue Committee approved the allotment of 3,67,60,483 equity shares at ₹99 each, in a 19:41 ratio, with a record date of 11th February 2026. Post-allotment, the paid-up equity share capital will be ₹1,16,08,57,370. Lapsed rights entitlements were extinguished.
The rights issue allotment and correction in face value have a moderate impact on the company's capital structure and investor perception.
The announcement primarily concerns a correction of information and the outcome of a rights issue, which is presented factually.
Stallion India Fluorochemicals Limited announced a correction to its earlier disclosure regarding the face value of equity shares. Due to a clerical error, the face value was initially mentioned as Re. 1/- instead of ₹10/-. The company has rectified this error in a revised outcome.
In a meeting held on 2nd March, 2026, the Rights Issue Committee of Directors approved the allotment of 3,67,60,483 (Three Crores Sixty-Seven Lakhs Sixty Thousand Four Hundred Eighty-Three) fully paid-up equity shares having a face value of ₹10 each on a rights basis. The shares were issued in the ratio of 19:41, meaning 19 rights equity shares for every 41 fully paid-up equity shares held by eligible shareholders. The issue price was ₹99 per equity share, with a record date of 11th February, 2026.
This allotment is pursuant to the Letter of Offer dated 12th February, 2026, and the Basis of Allotment approved by BSE Limited. Following the allotment, the paid-up Equity Share Capital of the Company will be 11,60,85,737 equity shares with a face value of ₹10 each, totaling ₹1,16,08,57,370. The committee also approved the extinguishment of lapsed rights entitlements and deactivation of ISIN INE0RYC20010.
What to do with a filing like this
Stallion India Fluorochemicals Limited filed this with the NSE as a statutory disclosure, categorised under rights issue. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Stallion India Fluorochemicals Limited. Read the original for the full detail.